Great news, he knows the FDA people who approved Dalvance (assuming some of them are still there) which is the drug that Brilacidin will be replacing or at least competing with. It looks like he retired from his salaried job and started a consulting firm. This is a very smart move for CTIX, being one of his first clients. He's going to do everything he can to get our drugs to approval, so that he can show other prospective clients that he's still got the moxie, and he knows key players and especially he knows the exact antibiotic space we're looking at for Brilacidin.

Once again Leo does the move that is good for the company's development, both on the scientific end and the financial end. You can bet he got a good deal on this, because you always have good negotiating power with a new company like this consultant.